Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Tencent/Netease: Under Pressure with No Game Approval in July

China Internet Weekly (18Jul2022): Tencent, Alibaba, Kingsoft Office, Miss Fresh

Tencent (700 HK): Game Industry Decreasing for First Time and Turning to Overseas Market

Tencent/Netease: China Game Approval Resumption Is a Relieve, but Not Out of Tunnel

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Tencent/Netease: Online Game Tightening Coming to an End

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>China announced game approval last night for June batch, after a break in May.</li>
<li>We discussed in our previous note that China had resume game approval but at a slower pace.</li>
<li>Tencent and Netease continue to score zero in June domestic game approval.</li>
</ul>


China announced game approval last night for June batch, after a break in May.
We discussed in our previous note that China had resume game approval but at a slower pace.
Tencent and Netease continue to score zero in June domestic game approval.


Tencent/Netease: Smell of Common Prosperity in June Game Approval